Tonix Pharmaceuticals Publishes P-III Results of TNX-102 SL in Military-Related PTSD in Psychiatry Research
Shots:
- The company highlighted the results of the P-III (HONOR) clinical trial evaluating the safety & efficacy of TNX-102 SL (Bedtime Sublingual Cyclobenzaprine) vs PBO in militants with PTSD. The 1EP of the study was an improvement from baseline in CAPS-5 total score at wk.12
- The study did not depict a statistically significant difference in 1EP with a nominal improvement by the wk.4 visit on CAPS-5 & unsustained improvement at wk.8 & wk.12 vs PBO
- The results also supported the P-II (OASIS) trial evaluating the efficacy of TNX-102 SL (5.6mg) in reducing the severity of ASR & the frequency of ASD in PTSD. Additionally, the publication will also highlight the results from the P-II (AtEase) & P-III (RECOVERY) trials
Ref: Tonix Pharmaceuticals | Image: Tonix Pharmaceuticals
Related News:- Tonix Pharmaceuticals Reports the Results for TNX-102 SL in P-III Trial for the Management of Fibromyalgia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
